Could dexmedetomidine-induced immunogenic cell death sensitize EBV-driven nasopharyngeal carcinoma to PD-1 blockade? A preclinical hypothesis and falsification framework

Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV)-driven epithelial malignancy characterized by persistent viral antigens but inefficient antigen presentation, dysfunctional dendritic cells, and exhausted T cells. Although programmed cell death protein 1 (PD-1) blockade has improved clinical outcomes, many patients do not achieve durable benefit. Dexmedetomidine (DEX) is an alpha2-adrenoceptor agonist used for sedation that was recently reported in a single preclinical study to induce immunogenic cell death (ICD) through partial endoplasmic reticulum stress, eIF2α phosphorylation, autophagy, surface calreticulin exposure, and HMGB1 and ATP release, effects that enhanced dendritic-cell uptake and cooperated with PD-1 blockade in non-NPC tumor models. This phenotype requires approximately 600 μM DEX, several orders of magnitude above the concentration range in which DEX engages the alpha2-adrenoceptor selectively, so the effect more likely reflects an off-target interaction than canonical receptor pharmacology. We propose that, if independently reproduced in EBV-positive NPC and traced to a defined molecular target, this phenomenon could enhance cross-presentation of EBV antigens and prime EBV-specific CD8+ T cells, providing an immunological rationale for combination with PD-1 blockade. This hypothesis is constrained by the exposure gap, the absence of independent or NPC-specific validation, context-dependent tumor-promoting and immunosuppressive effects, a DEX-associated T-cell exhaustion signature, and the unresolved identity of the responsible target. We therefore do not advocate systemic dose escalation or immediate interventional testing. Instead, we present a staged falsification framework requiring independent confirmation of canonical ICD, spatially resolved demonstration of antigen-specific cross-presentation and stromal T-cell infiltration, deconvolution of the molecular target through thermal proteomics and CRISPR-based screening, and exclusion of hemodynamic, metastatic, and immunosuppressive liabilities before efficacy testing in EBV-relevant models. Only if these criteria are satisfied should localized delivery, target-directed inducer design, or prospective clinical evaluation be considered. This Perspective repositions DEX as a phenotypic probe for target discovery rather than a repurposed receptor agonist or an established anticancer therapy.